Herbas VPB

Print
EN | LT
LT - Vėžio gydymo būdas, panaudojant imuninio kontrolinio taško inhibitorių; antikūnas, kuris prisiriša prie užprogramuotos mirties 1 receptoriaus (PD-1) arba prie užprogramuotos mirties ligando 1 (PD-L1)
EN - METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07K 16/28 (2006.01)
A61K 39/395 (2006.01)
G01N 33/574 (2006.01)
C12Q 1/6886 (2018.01)
A61K 39/00 (2006.01)
A61P 35/00 (2006.01)
C12Q 1/70 (2006.01)
European patent
(11) Number of the document 3322731
(13) Kind of document T
(96) European patent application number 16744626.9
Date of filing the European patent application 2016-07-14
(97) Date of publication of the European application 2018-05-23
(45) Date of publication and mention of the grant of the patent 2021-01-13
(46) Date of publication of the claims translation 2021-03-25
PCT application
(86) Number PCT/US2016/042297
Date 2016-07-14
PCT application publication
(87) Number WO 2017/011666
Date 2017-01-19
Priority applications
(30) Number Date Country code
201562192396 P 2015-07-14 US
Inventors
(72)
MANEKAS, Demetrios, US
GROSSO, Joseph, US
ANDERSON, Jeffrey, US
Grantee
(73) Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US
Attorney or representative
(74) Jurga PETNIŪNAITĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) Vėžio gydymo būdas, panaudojant imuninio kontrolinio taško inhibitorių; antikūnas, kuris prisiriša prie užprogramuotos mirties 1 receptoriaus (PD-1) arba prie užprogramuotos mirties ligando 1 (PD-L1)
  METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)
Last renewal fee
Payment date Validity (years) Amount
2025-06-04 10 231.00 EUR
Next renewal fee
2026-07-14